Holen Sie sich die Stockscreener-App
2.19
1.39%
0.03
Schlusskurs vom Vortag:
$2.16
Offen:
$2.13
24-Stunden-Volumen:
156.60K
Relative Volume:
0.58
Marktkapitalisierung:
$19.68M
Einnahmen:
$14.58M
Nettoeinkommen (Verlust:
$-12.57M
KGV:
-0.3856
EPS:
-5.68
Netto-Cashflow:
$-13.07M
1W Leistung:
+5.80%
1M Leistung:
-13.78%
6M Leistung:
+3.79%
1J Leistung:
-51.87%
1-Tages-Spanne:
$2.12
$2.28
1-Wochen-Bereich:
$2.04
$2.28
52-Wochen-Spanne:
$1.98
$7.95
Vivos Therapeutics Inc Stock (VVOS) Company Profile
Firmenname
Vivos Therapeutics Inc
Sektor
Branche
Telefon
(866)908-4867
Adresse
7921 SOUTHPARK PLAZA,, LITTLETON
Vergleichen Sie VVOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
2.19 | 19.41M | 14.58M | -12.57M | -13.07M | -5.68 |
|
ABT
Abbott Laboratories
|
122.55 | 210.84B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.70 | 137.17B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
353.80 | 133.55B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.77 | 127.71B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.92 | 48.33B | 5.88B | 1.34B | 799.60M | 2.3489 |
Vivos Therapeutics Inc Aktie (VVOS) Neueste Nachrichten
What analysts say about Vivos Therapeutics Inc stockPrice Momentum Alerts & What the Pros Are Saying About This Stock - earlytimes.in
Vivos Therapeutics secures $2M note with Avondale - MSN
Vivos Therapeutics Secures $2M Note with Avondale - TipRanks
Vivos Therapeutics, Inc. Enters into a Note Purchase Agreement with Avondale Capital, LLC - marketscreener.com
Can Vivos Therapeutics Inc. stock beat analyst upgradesJuly 2025 Closing Moves & High Accuracy Swing Entry Alerts - Newser
Is Vivos Therapeutics Inc. stock a buy for dividend growthEarnings Overview Summary & Low Drawdown Momentum Trade Ideas - Newser
Vivos Therapeutics, Inc. announced that it has received $2.09334 million in funding from Avondale Capital, LP - marketscreener.com
Vivos Therapeutics (NASDAQ:VVOS) Given New $5.50 Price Target at Ascendiant Capital Markets - Defense World
Is Vivos Therapeutics Inc. stock a smart buy before Fed meeting2025 Price Momentum & AI Enhanced Trading Alerts - Newser
VVOS: Ascendiant Capital Maintains Buy Rating, Lowers Price Targ - GuruFocus
Ascendiant Capital Maintains Vivos Therapeutics (VVOS) Buy Recommendation - Nasdaq
Vivos Therapeutics (VVOS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Vivos Therapeutics Reports Strong Q3 Growth Amid Challenges - MSN
Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga
Vivos Therapeutics Inc (VVOS) Q3 2025 Earnings Call Highlights: Revenue Surge Amid Strategic ... By GuruFocus - Investing.com Canada
Why Vivos Therapeutics Inc. stock remains on buy lists2025 Geopolitical Influence & High Accuracy Investment Signals - newser.com
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q3 2025 Earnings Call Transcript - Insider Monkey
Vivos Therapeutics Inc. (VVOS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Vivos Therapeutics Rides Acquisition Wave To Higher Revenue - Finimize
What is HC Wainwright’s Estimate for VVOS Q3 Earnings? - Defense World
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Receives $5.44 Average Target Price from Analysts - Defense World
Vivos Therapeutics Reports Revenue Growth Amid Strategic Shift - MSN
Published on: 2025-11-20 02:04:52 - newser.com
Earnings call transcript: Vivos Therapeutics Q3 2025 shows revenue growth By Investing.com - Investing.com Nigeria
Vivos Therapeutics signals continued revenue acceleration amid SCN integration and SAMC expansion plans - MSN
Vivos Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat
Why Vivos Therapeutics Inc. stock appeals to analystsFed Meeting & Technical Confirmation Alerts - newser.com
Earnings call transcript: Vivos Therapeutics Q3 2025 shows revenue growth - Investing.com India
What technical charts say about Vivos Therapeutics Inc. stockWeekly Gains Summary & Verified Entry Point Signals - newser.com
[8-K] Vivos Therapeutics, Inc. Reports Material Event | VVOS SEC FilingForm 8-K - Stock Titan
Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025 - The Globe and Mail
Vivos Therapeutics Q3 revenue rises, helped by SCN acquisition - marketscreener.com
Will Vivos Therapeutics Inc. continue its uptrendTake Profit & Verified Swing Trading Watchlist - newser.com
Vivos Therapeutics (NASDAQ: VVOS) reports 78% third quarter revenue growth - Stock Titan
[10-Q] Vivos Therapeutics, Inc. Quarterly Earnings Report | VVOS SEC FilingForm 10-Q - Stock Titan
Vivos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Vivos Therapeutics, Inc. Plans Q3 2025 Financial Results Release and Investor Conference Call - Quiver Quantitative
Vivos Therapeutics (NASDAQ: VVOS) to Release Q3 2025 Results, Host Call Today - Stock Titan
Vivos Therapeutics (NASDAQ:VVOS) Coverage Initiated at HC Wainwright - Defense World
HC Wainwright & Co. Initiates Coverage of Vivos Therapeutics (VVOS) with Buy Recommendation - Nasdaq
Finanzdaten der Vivos Therapeutics Inc-Aktie (VVOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):